Xiaopeng Yu

1.4k total citations · 1 hit paper
40 papers, 940 citations indexed

About

Xiaopeng Yu is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Xiaopeng Yu has authored 40 papers receiving a total of 940 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 12 papers in Oncology and 10 papers in Cancer Research. Recurrent topics in Xiaopeng Yu's work include Cholangiocarcinoma and Gallbladder Cancer Studies (6 papers), Inflammatory mediators and NSAID effects (6 papers) and Cancer-related molecular mechanisms research (5 papers). Xiaopeng Yu is often cited by papers focused on Cholangiocarcinoma and Gallbladder Cancer Studies (6 papers), Inflammatory mediators and NSAID effects (6 papers) and Cancer-related molecular mechanisms research (5 papers). Xiaopeng Yu collaborates with scholars based in China and United States. Xiaopeng Yu's co-authors include Steven Jenison, Denise A. Galloway, Srinivasan Chandrasekhar, Anna Marie Beckmann, Laura A. Koutsky, Audrey E. Christiansen, Puhua Zeng, Anita K. Harvey, Frank G. Hustmyer and Wenhui Gao and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Virology.

In The Last Decade

Xiaopeng Yu

37 papers receiving 918 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Polyphyllin I induced ferroptosis to suppress the progression of hepatocellular carcinoma through activation of the mitochondrial dysfunction via Nrf2/HO-1/GPX4 axis

2023 134 citations Wenhui Gao, Zhibing Wang et al. Phytomedicine profile →

Peers

Xiaopeng Yu

EPIDE

ONCOL

GENET

Barbara Bucci Italy

Elisa Schmoeckel Germany

Janina Markowska Poland

Sung‐Chul Lim South Korea

Wen Yuan Chung United Kingdom

Srinivas Chava United States

Tze‐Yi Lin Taiwan

Takahide Arimoto Japan

Hamid Asadzadeh Aghdaei Iran

Barbara Bucci Italy

Xiaopeng Yu

487 ×1.3

283 ×1.1

EPIDE

284 ×1.4

ONCOL

261 ×1.4

87 ×0.6

GENET

Citations per year, relative to Xiaopeng Yu Xiaopeng Yu (= 1×) peers Barbara Bucci

Countries citing papers authored by Xiaopeng Yu

Since Specialization

Citations

This map shows the geographic impact of Xiaopeng Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaopeng Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaopeng Yu more than expected).

Fields of papers citing papers by Xiaopeng Yu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaopeng Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaopeng Yu. The network helps show where Xiaopeng Yu may publish in the future.

Co-authorship network of co-authors of Xiaopeng Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaopeng Yu. A scholar is included among the top collaborators of Xiaopeng Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaopeng Yu. Xiaopeng Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yu, Xiaopeng, et al.. (2025). A multi-dimensional bioinformatic dissection of the molecular mechanisms in high-BMI–associated colorectal cancer: identification and validation of EGLN1 as a key target. International Journal of Surgery. 112(2). 2934–2948.

Wei, Peng, et al.. (2024). Construction and validation of a nomogram for cancer specific survival of postoperative pancreatic cancer based on the SEER and China database. BMC Gastroenterology. 24(1). 104–104. 2 indexed citations

Yu, Xiaopeng, et al.. (2024). CircEZH2 promotes gallbladder cancer progression and lipid metabolism reprogramming through the miR-556-5p/SCD1 axis. iScience. 27(8). 110428–110428.

Yu, Xiaopeng, et al.. (2023). Construction and validation of a SEER-based prognostic nomogram for young and middle-aged males patients with hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology. 149(12). 10099–10108. 2 indexed citations

Tang, Yue, et al.. (2023). ALOX5 acts as a key role in regulating the immune microenvironment in intrahepatic cholangiocarcinoma, recruiting tumor-associated macrophages through PI3K pathway. Journal of Translational Medicine. 21(1). 923–923. 12 indexed citations

Zhu, Danhua, Xiaoxi Ouyang, Yanhong Zhang, et al.. (2023). A promising new cancer marker: Long noncoding RNA EGFR-AS1. Frontiers in Oncology. 13. 1130472–1130472. 6 indexed citations

Gao, Hongli, Ce Ji, Xiaopeng Yu, et al.. (2023). Targeting ubiquitin specific proteases (USPs) in cancer immunotherapy: from basic research to preclinical application. Journal of Experimental & Clinical Cancer Research. 42(1). 225–225. 59 indexed citations

Yu, Xiaopeng, et al.. (2023). CircRNA MBOAT2 promotes intrahepatic cholangiocarcinoma progression and lipid metabolism reprogramming by stabilizing PTBP1 to facilitate FASN mRNA cytoplasmic export. Cell Death and Disease. 14(1). 20–20. 41 indexed citations

Gao, Wenhui, Zhibing Wang, Peng Lian, et al.. (2023). Polyphyllin I induced ferroptosis to suppress the progression of hepatocellular carcinoma through activation of the mitochondrial dysfunction via Nrf2/HO-1/GPX4 axis. Phytomedicine. 122. 155135–155135. 134 indexed citations breakdown →

10.

Yu, Xiaopeng, et al.. (2023). Construction and validation of a nomogram for hepatocellular carcinoma patients based on HCC-GRIm score. Journal of Cancer Research and Clinical Oncology. 149(13). 12013–12024. 1 indexed citations

11.

Yu, Xiaopeng, et al.. (2022). Establishment and experimental validation of a novel cuproptosis-related gene signature for prognostic implication in cholangiocarcinoma. Frontiers in Oncology. 12. 1054063–1054063. 3 indexed citations

12.

Wang, Ning & Xiaopeng Yu. (2022). Comparison between talazoparib and conventional chemotherapy in the treatment of HER2-positive breast cancer patients: A retrospective study. Frontiers in Immunology. 13. 901636–901636. 2 indexed citations

13.

Ho, Joseph D., Matthew R. Lee, Charles T. Rauch, et al.. (2020). Structure-based, multi-targeted drug discovery approach to eicosanoid inhibition: Dual inhibitors of mPGES-1 and 5-lipoxygenase activating protein (FLAP). Biochimica et Biophysica Acta (BBA) - General Subjects. 1865(2). 129800–129800. 17 indexed citations

14.

Zou, Jiahuan, Meng‐Wei Zhuang, Xiaopeng Yu, et al.. (2018). MYC inhibition increases PD-L1 expression induced by IFN-γ in hepatocellular carcinoma cells. Molecular Immunology. 101. 203–209. 46 indexed citations

15.

Liu, Ningning, Jiang‐Shan Tan, Xiaopeng Yu, et al.. (2018). Adrenal myelolipoma with hyperandrogenemia and schizophrenia. Cancer Management and Research. Volume 10. 177–180. 6 indexed citations

16.

Blanco, María‐Jesús, Tatiana Vetman, Srinivasan Chandrasekhar, et al.. (2016). Identification and biological activity of 6-alkyl-substituted 3-methyl-pyridine-2-carbonyl amino dimethyl-benzoic acid EP4 antagonists. Bioorganic & Medicinal Chemistry Letters. 26(9). 2303–2307. 10 indexed citations

17.

Blanco, María‐Jesús, Tatiana Vetman, Srinivasan Chandrasekhar, et al.. (2015). Discovery of potent aryl-substituted 3-[(3-methylpyridine-2-carbonyl) amino]-2,4-dimethyl-benzoic acid EP4 antagonists with improved pharmacokinetic profile. Bioorganic & Medicinal Chemistry Letters. 26(3). 931–935. 7 indexed citations

18.

Lv, Chao, et al.. (2013). The Efficacy of Additional Bevacizumab to Cytotoxic Chemotherapy Regimens for the Treatment of Colorectal Cancer: An Updated Meta-Analysis for Randomized Trials. Cancer Biotherapy and Radiopharmaceuticals. 28(7). 501–509. 11 indexed citations

19.

Harvey, Anita K., Xiaopeng Yu, Charles A. Frolik, & Srinivasan Chandrasekhar. (1999). Parathyroid Hormone-(1–34) Enhances Aggrecan Synthesis via an Insulin-like Growth Factor-I Pathway. Journal of Biological Chemistry. 274(33). 23249–23255. 31 indexed citations

20.

Yu, Xiaopeng & Srinivasan Chandrasekhar. (1997). Parathyroid Hormone (PTH 1–34) Regulation of Rat Osteocalcin Gene Transcription. Endocrinology. 138(8). 3085–3092. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact